

Editorial



EDITORIAL

Dear Reader,

Firstly, I extend my warm greetings to you. In the Fourth issue we have selected 07 papers out of which 04 are research articles and others are review articles and Survey based works. I would also like to add that we have been indexed to ISSN. Being an open access journal we offer instant access to works published in the journal for scholars to refer and reach out for further communication and thereby thrive a better culture for cooperation.

As we are aware that medical science is on the road of constant threats from emerging diseases, platforms to communicate finding becomes essential. The recent incidents of Ebola Virus infections are a vivid reminder of the importance of quest for new drugs. Judicial use of existing therapy should also be of prime importance in order to avoid drug resistance.

Meanwhile, the clinical trial sector of India is under turbulence following new regulations being introduced last year by The Supreme court and Government for human trials. This year only 25 trials have been approved as compared to average of 200 trial approvals prior the new regulations came into effect. 2013 saw approval of 35 new drugs whereas only 7 being approved till now this year. The clinical trials will become more expensive owing to the withdrawal of service tax exemption from Indian and foreign drug companies and CROs as proposed in the last budget by Finance Minister Mr. Arun Jaitly. Analysts projects that the cost might increase by as much as 12.3% if the budget comes into effect.

Both Pharma & CRO industry expressed concern over the matter as they pointed out that tax incentives encourages the R&D and offer assistance. Being the second most populous country in the world and comparatively less cost to conduct trial has been the key point in favor of the Indian clinical sector. The Indian Society of Clinical Research has opposed the decision.

Therefore the decision must be weighed for benefit/outcome ratio and the aftermath on such a vital sector. We hope the decision must be reviewed and debated before it comes into effect.

Enjoy the reading.

Warm Regards,

Ankur Bakshi
Editorial Member

Indian Research Journal of Pharmacy and Science; 4(2015)- i ;
Journal home page: <https://www.irjps.in>